Novartis Ag (NVS) Cash & Equivalents (2009 - 2025)

Novartis Ag's Cash & Equivalents history runs 12 years deep, the most recent figure standing at $2.6 billion for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 965.7% year-over-year to $2.6 billion; the TTM figure through Dec 2025 stood at $2.6 billion (up 965.7% YoY), while the FY2025 annual figure was $2.6 billion, up 965.7% from the prior year.
• Cash & Equivalents came in at $2.6 billion for Q4 2025 at Novartis Ag, down from $6.7 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $13.4 billion in Q4 2023 to a low of $6.0 million in Q1 2021.
• A 5-year average of $4.5 billion and a median of $3.1 billion in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 1066.67% in 2022 and tumbled 98.19% in 2024, its largest moves.
• Novartis Ag's Cash & Equivalents stood at $12.4 billion in 2021, then slumped by 39.41% to $7.5 billion in 2022, then soared by 78.17% to $13.4 billion in 2023, then sank by 98.19% to $242.0 million in 2024, then jumped by 965.7% to $2.6 billion in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $2.6 billion, $6.7 billion, and $242.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison